Main Article Content
Millions of people are affected globally by alzheimer’s disease and it is regarded as a dangerous progressive medical and socio-economic burden. The drug delivery to brain is hindered due to the presence of blood brain barrier. Nanoparticle mediated drug delivery is a promising approach in this regard. Chitosan is a hydrophilic polysaccharide polymer of N-acetylglycosamine and glucosamine. Owing to its biodegradability, nontoxicity and biocompatibility it is regarded as a safe excipient. The aim of the study was to fabricate donepezil-loaded sustained release chitosan nanoparticles as a simple way to deliver nano-drugs to the brain. The nanoparticles were fabricated using ionic gelation method using different concentrations of Sodium tripolyphosphate (TPP) and chitosan. The fabricated nanoparticles were assessed for particle size, zeta potential, encapsulation efficiency and in vitro drug release. The effect of sonication time on the particle size of nanoparticles was also studied. The nanoparticles exhibited mean particle size (between 135-1487 nm) and zeta potential (between +3.9-+38mV) depending on chitosan and TPP concentration used. The rise in the sonication time from 25 to 125 sec exhibited a decrease in particle size. The encapsulation efficiency was found to be in the range of 39.1-74.4%. Sustained and slow release of donepezil at a constant rate was exhibited from nanoparticles. The nanoparticles show potential to deliver donepezil to brain with enhanced encapsulation efficiency.
Zhang HY. One-compound-multipletargets strategy to combat Alzheimer’s disease. FEBS Lett. 2005;579(24):5260-4.
Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across blood–brain barrier. Drug Dev. Ind. Pharm. 2002;28(1):1–13.
Zhang M, Schmitt-Ulms G, Sato C, Xi Z, Zhang Y, Zhou Y, George-Hyslop PS, Rogaeva E. Drug Repositioning for Alzheimer’s Disease Based on Systematic “omics” Data Mining. PLoS ONE. 2016;11: e0168812.
Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003;20(3): 409–16.
Shuting K, Feng Y, Ying W, Yilin S, Nan Y, Ling Y. The blood–brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem. Biophys. Res. 2010;394 (4):871–6.
Hai H, Yan L, Xin RJ, Ju D, Xue Y, Wan-L L et al. The blood–brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biomaterials. 2011;32(4):478-87.
Ganeshchandra S, Keishiro T, Kimiko M. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids and Surfaces B: Biointerfaces. 2008;66(2):274–80.
Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer’s Res. Ther. 2014;6:37.
A Elman J, Oh H, Madison CM, Baker SL, Vogel JW, Marks SM, Crowley S, O’Neil JP, Jagust WJ. Neural compensation in older people with brain amyloid-β deposition. Nat. Neurosci. 2014;17:1316–1318.
Singh SK, Srivastav S, Yadav AK, Srikrishna S, Perry G. Overview of Alzheimer’s disease and some therapeutic approaches targeting Aβ by using several synthetic and herbal Compounds. oxidative med. Cell. Longev. 2016;1–22.
Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesive: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;28(4):353-69.
Reichmann WE. Current pharmacologic options for patients with Alzheimer’s disease. Ann Gen Hosp Psychiatr. 2003;2 (1):1.
Arya G, Vandana M, Acharya S, Sahoo, SK. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated Gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomed. Nanotechnol. Biol. Med. 2011;7(6):859– 70.
Siram K, Vijaya Raghavan C, Tamilselvan N, Balakumar K, Habibur Rahman SM, Vamshi Krishna K, et al. Solid lipid nanoparticles of diethylcarbamazine citrate for enhanced delivery to the lymphatics: in vitro and in vivo evaluation. Expert Opin. Drug Deliv. 2014;11(8):1-15.
Butterfield DA, Swomley AM, Sultana R. Amyloid β-Peptide (1–42)-induced oxidative stress in alzheimer disease: Importance in Disease Pathogenesis and Progression. Antioxid. Redox Signal. 2013; 19:823–835.
Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C et al. “DD Solver: An add-in program for modelling and comparison of drug dissolution profiles.” AAPS Journal. 2010; 12(3):263–71.
Wang F Zhou XL, Yang QG, Xu WH; Wang F, Chen YP, Chen GH. A Peptide that binds specifically to the β-amyloid of Alzheimer’s disease: Selection and Assessment of Anti-β-Amyloid Neurotoxic Effects. PLoS ONE. 2011;6:e27649.
Emmanuel NK, Sofia AP, Dimitrios NB, George EF. Insight on the Formation of Chitosan anoparticles through Ionotropic Gelation with Tripolyphosphate. Molecular Pharmaceutics. 2012;9(10):2856−62.
Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: Similarities and differences. Fluids Barriers CNS. 2011;8(3).
Pardridge WM. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx. 2005;2:3–14.
Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9:S3.
Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua, S. Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol. 2015;6:286.
Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. Int. J. Pharm. Investig. 2012;2:2–11.
Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science. 2004;303:1818–1822.